Saint Maria Hospital

Futó vizsgálatok

• Még nem toboroz

  Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.

  2026-526419-13-00· 3. fázis· Forrás

• Még nem toboroz

  A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)

  NCT07760818· 2. fázis· Forrás

• Toboroz

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· 3. fázis· Forrás

• Még nem toboroz

  A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)

  2025-522471-28-00· 3. fázis· Forrás

• Toboroz

  Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

  NCT07404865· 3. fázis· Forrás

• Fut, nem toboroz

  Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease

  2024-516295-14-00· 2. fázis· Forrás

• Fut, nem toboroz

  Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

  NCT06979531· 2. fázis· Forrás

• Fut, nem toboroz

  A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs

  2024-516213-20-00· 3. fázis· Forrás

• Fut, nem toboroz

  Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

  NCT06843239· 2. fázis· Forrás

• Fut, nem toboroz

  Nipocalimab in Moderate to Severe Sjogren's Disease

  NCT06741969· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

  NCT06655155· 2. fázis· Forrás

• Toboroz

  Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

  NCT06133972· 3. fázis· Forrás

• Fut, nem toboroz

  Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

  NCT05925803· 3. fázis· Forrás

• Fut, nem toboroz

  A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

  NCT05985915· 3. fázis· Forrás

• Fut, nem toboroz

  Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

  NCT05843643· 3. fázis· Forrás

• Toboroz

  Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1)

  2022-500699-76-00· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

  NCT05622708· 4. fázis· Forrás

• Toboroz

  A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

  NCT04697810· 2. fázis· Forrás

• Fut, nem toboroz

  The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

  NCT05540327· 2. fázis· Forrás

• Fut, nem toboroz

  Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

  NCT05126277· 3. fázis· Forrás

• Fut, nem toboroz

  A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

  NCT04895696· 2. fázis· Forrás

• Fut, nem toboroz

  A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

  NCT04908202· 3. fázis· Forrás

• Fut, nem toboroz

  A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

  NCT02629159· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Lupus (SLE)3 toboroz
• Sjögren-szindróma2 toboroz
• Arthritis psoriatica1 toboroz
• Szisztémás szklerózis (szkleroderma)1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in rheumatoid arthritis

  2024-510826-16-00· 3. fázis· Forrás

• Lezárult

  A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis

  2023-506664-14-00· 3. fázis· Forrás

• Lezárult

  Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

  NCT05814627· 3. fázis· Forrás

• Fut, nem toboroz

  Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

  NCT05624749· 3. fázis· Forrás

• Lezárult

  A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis

  NCT04781543· 2. fázis· Forrás

• Lezárult

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· 2. fázis· Forrás

• Fut, nem toboroz

  Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

  NCT05349214· 3. fázis· Forrás

• Lezárult

  The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

  NCT05162586· 2. fázis· Forrás

• Lezárult

  A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis

  2023-509782-20-00· 2. fázis· Forrás

• Lezárult

  A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964· 4. fázis· Forrás

• Fut, nem toboroz

  A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

  NCT03675308· 3. fázis· Forrás